1. Home
  2. PLBY vs CHRS Comparison

PLBY vs CHRS Comparison

Compare PLBY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.18

Market Cap

204.4M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.67

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
CHRS
Founded
1953
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.4M
209.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PLBY
CHRS
Price
$1.18
$1.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$5.51
AVG Volume (30 Days)
990.7K
966.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
472.00
EPS
N/A
N/A
Revenue
$120,928,000.00
N/A
Revenue This Year
$9.17
$73.08
Revenue Next Year
$7.10
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
4.13
N/A
52 Week Low
$1.19
$0.80
52 Week High
$2.75
$2.62

Technical Indicators

Market Signals
Indicator
PLBY
CHRS
Relative Strength Index (RSI) 33.85 62.68
Support Level N/A $1.55
Resistance Level $1.94 $1.79
Average True Range (ATR) 0.09 0.10
MACD -0.02 0.03
Stochastic Oscillator 2.33 89.47

Price Performance

Historical Comparison
PLBY
CHRS

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: